var configs = {
    "menu": [{
            "name": "About Us",
            "href": "#about"
        },
        {
            "name": "Our Business",
            "href": "#business"
        },
        {
            "name": "Our Team",
            "href": "#team"
        },
        {
            "name": "News",
            "href": "#news"
        },
        {
            "name": "Event",
            "href": "#investor"
        },
        {
            "name": "contact Us",
            "href": "#contact"
        },
        {
            "name": "ç¹",
            "href": "#lang#tc"
        },
        {
            "name": "ç°¡",
            "href": "#lang#ts"
        },
    ],
    "home": {
        "text": "Welcome to Aptorum",
        "banners": [{
                "path": "images/home/banner1.jpg",
                "text": "To Tackle Key Global Health Challenges and Unmet Needs<br>",
                "color": "#FFF",
            },
            {
                "path": "images/home/banner2.jpg",
                "text": "To Propel Innovations in Healthcare and Life Science",
                "color": "#000",
            },
            {
                "path": "images/home/banner3.jpg",
                "text": "Collaborating with Leading Professionals<br>",
                "color": "#000",
            },
        ],
    },
    "aboutus": {
        "title": "About Aptorum",
        "text": "Aptorum Group Limited (“Aptorum Group” or “The Company”) is a Hong Kong-based life science and biopharmaceutical company dedicated to acquiring, developing and commercializing novel biopharmaceutical products and innovations around the world. </br>  By collaborating with the world’s leading universities and scientific institutions, we actively seek product candidates which tackle key global health challenges and address unmet medical needs. Also, by leveraging on our business network and efficient management, Aptorum facilitates our portfolio companies to unleash their life science development capabilities that propel innovative solutions for healthcare advancement. </br> As of December 2017, Aptorum Group has obtained 11 exclusive licenses covering neurology, infectious diseases, gastroenterology, oncology, surgical robotics and natural health, etc. </br> Additionally, we are dedicating resources to develop a worldwide medical clinics network (commencing in Hong Kong initially), which assembled with talented clinicians and surgical experts, to address the demand for high quality healthcare services in the region.",
        "vision":{
            "title":"Our Vision",
            "bullets":  [{"text": "Facilitating life science technologies from bench to beside"},
                         {"text": "To tackle key global health challenges and unmet needs"},
                         {"text": "To propel innovations in healthcare and life science"},
                        ]
        },
        "organization": {
            "title": "Our Organization",
            "text": "<p>Our business consists of a â€œtherapeuticsâ€ business segment and a â€œnon therapeuticâ€ business segment</p>",
            "services": [{
                    "name": "Therapeutics",
                    "text": "Therapeutics segment is dedicated to clinical development of its biopharmaceutical drugs, food supplements, and diagnostic drugs and devices, whose business includes the licensing, strategic acquisition, development and protection of intellectual property (â€œIPâ€), as well as seeking regulatory and marketing approval of IP and technologies with the intent to develop such innovations towards commercialization in key global markets.",
                    "icons": "images/icons/Button1.png"
                },
                {
                    "name": "Non-therapeutics",
                    "text": "Non-therapeutics segment encompasses non-drug development or non-therapeutic related businesses, (e.g. robotic surgery and medical devices) and is planning to develop and making strategic acquisitions of clinics and hospitals, with the aim of creating advanced medical innovation centers and clusters worldwide.",
                    "icons": "images/icons/Button2.png"
                },
            ]
        },
        "story":{
            "title":"Our Story",
            "paragraphs":  [{"text": "In November 2002, an outbreak of Severe Acute Respiratory Syndrome (SARS) began in Guangdong Province of the PRC, which has then bordered on Hong Kong in March 2003."},
                            {"text": "Our Chairman – Mr. Ian Huen, his father was unfortunately confirmed as one of the sufferers from SARS in Hong Kong, and for this reason, his whole family was forced to be quarantined. At that juncture, Mr. Ian Huen was so dedicated that a curative solution for SARS can be found by the research team which led by Professor Kwok-Yung Yuen of The University of Hong Kong. Finally, the World Health Organization (\“WHO\”) declared that SARS was contained in July 2003 and Mr. Ian Huen’s father has recovered from the disease."},
                            {"text": "This incident has provoked the passion of Mr. Ian Huen to invest in life science and biopharmaceutical projects, and highlighted that Hong Kong as the world city of Asia, has many talented medical specialists with outstanding international academic reputation, knowledge and track record."},
                        ]
        },
        "partnership": {
            "title": "Our Partnership",
            "text":"Aptorum is actively seeking partners in the development of novel biopharmaceutical products and innovations, and has entered into multiple collaborations with leading academic and clinical research groups, to extend the reach of innovative therapies to more patients and the greater healthcare community.",
            "partners": {
                "university": {
                    "title": "University",
                    "col1": [{
                            "path": "images/partner/harvard.png",
                            "text": "Harvard University"
                        },
                        {
                            "path": "images/partner/hkbu.png"
                        },
                        {
                            "path": "images/partner/hkcu.png",
                            "text": "The Chinese University of Hong Kong (CUHK)"
                        },
                        {
                            "path": "images/partner/hku.png",
                            "text": "The University of Hong Kong (HKU)"
                        },
                    ],
                    "col2": [{
                            "path": "images/partner/manu.png",
                            "text": "The University of Manchester"
                        },
                        {
                            "path": "images/partner/ucl.png"
                        },
                        {
                            "path": "images/partner/oxford.png",
                            "text": "University of OXFORD"
                        },
                        {
                            "path": "images/partner/polyu.png",
                            "text": "The Hong Kong Polytechnic University"
                        },
                    ]
                },
                "institution": {
                    "title": "Research institution and pharmaceuticals",
                    "col1": [{
                            "path": "images/partner/icr.png"
                        },
                        {
                            "path": "images/partner/mpi.png",
                            "text": "MPI Research"
                        },
                    ],
                    "col2": [{
                            "path": "images/partner/oxstem.png"
                        },
                        {
                            "path": "images/partner/sttarr.png",
                            "text": "The STTARR (Spatio-temporal Targeting and Amplification of Radiation Response)"
                        },
                        {
                            "path": "images/partner/uhn.png",
                            "text": "University Health Network"
                        },
                    ]
                },
                "association": {
                    "title": "Association",
                    "col1": [{
                            "path": "images/partner/mada.png",
                            "text": "Macau Alzheimer’s Disease Association"
                        },
                        {
                            "path": "images/partner/cdra.png",
                            "text": "The Chinese Dementia Research Association Ltd"
                        },
                    ],
                },
            }
        }
    },
    "business": {
        "title": "",
        "text": "",
        "banners": [
            {
                "path": "images/business/business1.jpg",
                "text": "Leverage on our academic relationships, business network and life science development capabilities to facilitate products development",
                "color": "#FFF",
            },
            {
                "path": "images/business/business2.jpg",
                "text": "Being selective on potential therapeutic innovations with scientific quality and promising market demand prospects",
                "color": "#FFF",
            },
            {
                "path": "images/business/business3.jpg",
                "text": "Create a portfolio of commercialized therapeutic products and products in development to ensure consistent development quality, commercial objectives and make value for shareholders",
                "color": "#000",
            },
        ],
        "modal":{
            "title":"Our Business",
            "text1": "Our primary objective is to propel innovations in healthcare and life science that tackle key global health challenges and unmet medical needs, and to maximize the global commercial value of our product candidates. Aptorum Group owns/operates the project companies which license IP patents and are dedicated to clinical development of our product candidates, as well as development of a worldwide medical clinic network to address the demand for high quality healthcare services.",
            "text2": "We have adopted three core strategies to empower our business development and maximize values.",
            "bullets":  [{"text": "Leverage on our academic relationships, business network and life science development capabilities to facilitate product development"},
                         {"text": "Being selective on potential therapeutic innovations with scientific quality and promising market demand prospects"},
                         {"text": "Build up a portfolio of commercialized products and products in development to diversify the risks typically associated with biopharmaceutical development and make numerous income streams and create values for shareholders"},
                        ],
            "text3": "Our business consists of a `therapeutics` business segment and a `non therapeutic` business segment ",
            "image": "images/orgchart.png",


            "businesses":[
                {
                    "title":"Therapeutics",
                    "text1": "Therapeutics segment is dedicated to clinical development of its biopharmaceutical drugs, food supplements, and diagnostic drugs and devices, whose business includes the licensing, strategic acquisition, development and protection of intellectual property (\“IP\”), as well as seeking regulatory and marketing approval of IP and technologies with the intent to develop such innovations towards commercialization in key global markets.",
                    "text2": "We own/control and operate the project companies which license IP patents and are dedicated to clinical development of our product candidates. We also intend to generate income through, for example, royalty rights or sub-licensing arrangements to ensure consistent development quality, commercial objectives and management across the Aptorum Group companies.",
                    "bullets":  [{  "title": "Videns (Neurology)",
                                    "text":"Focused on the large-scale strategic clinical development in neurodegenerative disease and imaging diagnosis innovation. Videns will be able to deliver a strong and diversified portfolio of medical imaging and drug treatment products in the field of neurodegenerative diseases and reshape such global landscape."
                                 },
                                 {  "title": "Acticule (Infectious Disease)",
                                    "text": "Acticule is a Spin-off Company of The University of Hong Kong, focusing on novel drug discovery and clinical therapeutic development in infectious disease related medical indications. Major product categories focus on antiviral and bacteria anti-virulence candidates and potential oral and injectable drugs."
                                 },
                                 {  "title": "Claves (Gastroenterology)",
                                    "text": "Claves focuses on the clinical development of therapeutic candidates related to the field of gastroenterology. The potential candidates under review and potentially developed focus on the removal of gut microbiota derived metabolites, with the purpose to prevent dysbiosis. Claves is also considering the possibilities of establishing a gut microbiota regulation platform with the objective to create a sustainable pipeline for therapeutic candidates to sequestrate metabolites with high affinity and specificity."
                                 },
                                 {  "title": "Scipio (Oncology)",
                                    "text": "Scipio focuses on the development of drugs and diagnostic methods in the field of oncology. Scipio’s current key project involves novel anti-cancer agents in the form of novel quinoline derivatives as new anti-cancer drugs and the molecular oncology of esophageal carcinoma."
                                 },
                                 {  "title": "Nativus (Natural Health)",
                                    "text": "Nativus focuses on Natural Health or the development of therapeutic drugs and food supplements based on extracts from natural ingredients, such as garlic and Chinese yam. Applications primarily focus on the women’s health sector and vision care. Nativus’ current lead candidate focuses on the treatment of endometriosis and the alleviation of pain symptoms due to dysmenorrhea commonly affecting women."
                                 },
                                 {  "title": "Aptorum Pharmaceutical Development (Formulation, CMC, Toxicology)",
                                    "text": "Aptorum Pharmaceutical Development (“APD”) operates an in-house pharmaceutical development center. The primary mission of the center is (i) to engage in GMP grade preclinical development of Aptorum Groups product candidates and assets with the ultimate objective of enabling them to enter first-in-human clinical trials; and (ii) to provide consultation and contract research work for clients."
                                 }
                                ]

                },
                {
                    "title":"Non-Therapeutics",
                    "text1": "Non-therapeutics segment encompasses non-drug development or non-therapeutic related businesses, (e.g. robotic surgery and medical devices) and is planning to develop and making strategic acquisitions of clinics and hospitals, with the aim of creating advanced medical innovation centers and clusters worldwide.  Our business objective is to capitalize strategically and facilitate the development of a large range of innovations with clinical and commercial potential made by our subsidiaries – Signate Life Sciences Limited and Aptorum Medical Limited. We believe the two companies will have significant synergies in the future, whereby, for example, Aptorum Medical Limited can act as the commercialization doorway toward our robotic surgical devices and A.I. driven innovations. ",
                    "text2": "",
                    "bullets":  [{  "title": "Signate (Robotic surgery)",
                                    "text":"Dedicating resources toward the prospective development of robotic driven surgical devices, as well as medical analytics technology based on artificial intelligence (“A.I.”).  We believe there is a significant market opportunity in merging robotic surgical devices and A.I. driven medical analytics to enhance surgical processes; this combined application has great potential for future development. "
                                 },
                                 {  "title": "Aptorum Medical Limited (medical clinic)",
                                    "text": "As a prospective business, we will also be dedicating resources toward the set up and operation of medical clinics (commencing in Hong Kong initially) over the next 3 years to attract medical and surgical talent to our group and to address the shortage of good quality healthcare and medical clinics in the region. "
                                 }]
                },
            ],
        }
    },
    "team": {
        "teams": [
            {
                "id":"bods",
                "name": "Board of Directors",
                "text": "The Board of Directors governs Aptorum Group in accordance with its vision, mission and values. Aptorumâ€™s directors have extensive medical, governance and financial experience and relationships throughout the healthcare industry. The role of the Board of Directors is to ensure that the company is well managed by having its units fulfilling their roles and responsibilities.",
                "icons": "images/icons/Button4.png",
                "icons_overlay": "images/icons/Button4_overhit.png",
                "members":[
                    {
                        "name":"Mr. Ian Huen",
                        "img":"images/team/ianhuen.png",
                        "title":"Founder, Chief Executive Officer, and Executive Director, Aptorum Group Limited",
                        "text":"<p>Mr. Ian Huen is the Founder, Chief Executive Officer and executive director of Aptorum Group Limited. Mr. Huen is also the Managing Director and founder of Hong Kong-based Aptus Capital Limited (formerly known as Guardian Capital Management Limited) established and regulated by the Hong Kong Securities and Futures Commission as a Type 9 Asset Manager since 2005. He has over 15 years of global asset management experience and previously covered the U.S. healthcare sector as an equity research analyst at Janus Capital. Mr. Huen was the financial adviser in the sale of Seng Heng Bank Limited (Macau) to Industrial and Commercial Bank of China (&ldquo;ICBC&rdquo;) in 2007.</p><p>As a trustee board member of the Dr. Stanley Ho Medical Development Foundation, Mr. Huen facilitates advisory, development funding, and access to research resources across Asia and continues to establish relationships with leading academic institutions to propel innovations in healthcare.</p><p>In addition, Mr. Huen acted as a panelist and speaker for Euromoney, S&amp;P and the Middle East Investment Summit (&ldquo;MEIS 2017&rdquo;).</p><p>Mr. Huen graduated from Princeton University with an A.B. degree in Economics in June 2001, earned a MA in Comparative and Public History from The Chinese University of Hong Kong (&ldquo;CUHK&rdquo;) in June 2016, and a Chartered Financial Analyst (&ldquo;CFA&rdquo;).</p>",
                    },
                    {
                        "name":"Mr. Darren Lui",
                        "img":"images/team/darrenlui.png",
                        "title":"President, Chief Business Officer, and Executive Director, Aptorum Group Limited",
                        "text":"<p>Mr. Darren Lui is the President, Chief Business Officer and executive director of Aptorum Group Limited.</p><p>Mr. Lui was previously the founder, director and responsible officer of Varengold Capital Securities Limited and Varengold Capital Asset Management Limited in Hong Kong, with subsidiaries operating brokerage, asset management, and investment businesses in Asia established since January 2015.</p><p>Prior to this, he was a Director within the Structured Capital Markets Group of Barclays Capital, where he spent more than nine years from September 2005 to February 2014 developing and establishing their London, Singapore and New York structuring teams.</p><p>From September 2002 to August 2005 he qualified as a Chartered Accountant with Ernst &amp; Young LLP (London), specializing in capital markets advisory.</p><p>Mr. Lui graduated with First Class Honors from Imperial College, London with a BSc degree in Biochemistry in June 2002. He is a Chartered Accountant (ICAS), a Chartered Financial Analyst (&ldquo;CFA&rdquo;), and an Associate of Chartered Institute of Securities &amp; Investments (UK).</p>",
                    },
                    {
                        "name":"Mr. Clark Cheng",
                        "img":"images/team/clarkcheng.png",
                        "title":"Chief Medical Officer and Executive Director, Aptorum Group Limited<br>Executive Director, Aptorum Medical Limited",
                        "text":"<p>Dr. Clark Cheng is the Chief Medical Officer and executive director of Aptorum Group. Immediately prior to this appointment, Dr. Cheng joined Raffles Medical Group in 2009 as the Operations Director and promoted to Deputy General Manager in 2011 that further expanded his role in the region. During his employment with Raffles Medical Group, he practiced as a full-time medical administrator to overlook Raffles Medical Hong Kong operations and support the group&rsquo;s development in China.</p><p>Dr. Cheng received his medical training at the University College London, UK in 2005 and completed his Foundation Year training at The Royal Free Hospital. Pursuing his career in surgery, he obtained his membership of the Royal College of Surgeons of Edinburgh in 2009 and commenced his training in Orthopaedics where he practiced as Specialist Registrar at the National University Hospital, Singapore with special interest in Traumatology of the lower limbs. In 2011, he also obtained his Master in Business &amp; Administration with distinction from Tippie College of Business, University of Iowa, US.</p><p>Dr. Cheng is an active member of the Singapore Chamber of Commerce and appears regularly as a guest speaker for Open University of HK, HK Airport Authority and other corporate events.</p>",
                        // "remark":"Appointments to commence in January 2018",
                    },
                    {
                        "name":"Professor Justin Wu",
                        "img":"images/team/justinwu.png",
                        "title":"Independent Non-Executive Director, Aptorum Group Limited",
                        "text":"<p>Professor Justin Wu is an independent non-executive director of Aptorum Group Limited. He has been serving as the Associate Dean of the Faculty of Medicine at The Chinese University of Hong Kong (&ldquo;CUHK&rdquo;) since July 2014, a Professor in the Department of Medicine and Therapeutics since 2009, also the Director of the S. H. Ho Center for Digestive Health, specializing in functional gastrointestinal diseases, reflux and motility disorders, and digestive endoscopy. Active in research publications and assessments, Professor Wu is currently the International Associate Editor of American Journal of Gastroenterology (&ldquo;AJG&rdquo;), and Managing Editor of Journal of Gastroenterology and Hepatology (&ldquo;JGH&rdquo;). He is also the Scientific Chairman of the Asian Neurogastroenterology and Motility Association (&ldquo;ANMA&rdquo;), and Honorary Treasurer of the Asian Pacific Association of Gastroenterology (&ldquo;APAG&rdquo;).</p><p>Professor Wu has won a number of awards including the Emerging Leader in Gastroenterology Award by the JGH Foundation, and the Vice Chancellor&rsquo;s Exemplary Teaching Award at CUHK. Aside from his expertise in gastroenterology, Professor Wu has an extensive interest in the development of Integrative Medicine in Hong Kong. He is currently serving as the Director of the Hong Kong Institute of Integrative Medicine, working closely with the School of Chinese Medicine to develop an integrative model at an international level. The institute aims to maximize the strength of Western and Chinese medicine to provide a safe and effective integrative treatment to patients.</p><p>Professor Wu is a consultant and an advisory board member for Takeda Pharmaceutical, AstraZeneca and Abbott Laboratory. He earned degrees in Bachelor of Medicine and Bachelor of Surgery from 1987 to 1993, and obtained his Medical Degree in 2000 all from CUHK. Additionally, he attained Fellowships of the Royal College of Physicians of Edinburgh and London in 2007 and 2012 respectively, Fellowship of the Hong Kong College of Physicians in 2002, Fellowship of the Hong Kong Academy of Medicine in 2002, and has been an American Gastroenterological Association Fellow since 2012.</p>",
                    },
                    {
                        "name":"Dr. Mirko Scherer",
                        "img":"images/team/mirkoscherer.png",
                        "title":"Independent Non-Executive Director, Aptorum Group Limited",
                        "text":"<p>Dr. Mirko Scherer is an independent non-executive director of Aptorum Group Limited. Dr. Scherer has also been serving since March 2015 as Managing Partner at TVM Capital Life Science office in Hong Kong, investing into innovative biotech, pharmaceutical, and medtech companies in Europe, Canada, the U.S. and Asia. Dr. Scherer is an experienced biotechnology executive and has led numerous financing and M&amp;A transactions, in both public and private markets, in Europe and the U.S. over 20 years. He consulted as an Entrepreneur in Residence from July 2012 to December 2014 for MPM Capital, focusing on deal sourcing for MPM in Europe. Dr. Scherer was also a cofounder and partner from November 2008 to February 2014 at KI Kapital, which specialized in consulting in the life science industries.</p><p>Prior to working in the venture capital industry, Dr. Scherer co-founded GPC Biotech (Munich and Princeton, NJ) in served as Chief Financial Officer from October 1997 to December 2007. GPC Biotech engaged in numerous pharmaceutical alliances with companies such as Sanofi Aventis, Boehringer Ingelheim, Altana (now part of Takeda), Yakult, and Pharmion (now part of Celgene). Over the last 20 years, Dr. Scherer has established an extensive network in the U.S. and European biotechnology and venture capital industry. Prior to his time at GPC Biotech Dr. Scherer worked as a consultant from May 1993 to June 1994 at the Boston Consulting Group. He has served on the Board of the Frankfurt Stock Exchange and is a board member of the Stichting Preferente Aandelen QIAGEN since 2004. Dr. Scherer earned a Doctorate in Finance from the European Business School in Oestrich-Winkel/Germany in 1998, a MBA from Harvard Business School in June 1996, and a degree in Business Administration from the University of Mannheim/Germany in February 1993.</p>",
                    },
                    {
                        "name":"Mr. Charles Bathurst",
                        "img":"images/team/charlesbathurst.png",
                        "title":"Independent Non-Executive Director, Aptorum Group Limited",
                        "text":"<p>Mr. Bathurst is an independent non-executive director of Aptorum Group Limited. Since 2012, he has also been serving as a Director at Summerhill Advisors Limited in London, U.K., a company that provides corporate and marketing advice to established companies on their new business and early stage company activities. Mr. Bathurst primarily focuses on corporate positioning, marketing, sales, management structure, and corporate governance.</p><p>Prior to his role with Summerhill, he served as a Director for J.O. Hambro Investment Management from September 2008 to August 2011 where he was in charge of restructuring and commercializing a range of in-house funds. He was appointed to the management board and also supervised reporting teams including accounting teams, financial controllers, regulatory reporting teams and internal control issues.</p><p>From April 2004 to March 2008, Mr. Bathurst served in multiple roles at Old Mutual Asset Managers (UK)including being a member of the senior management team and director of international sales. Duties included business development, recruitment, establishing and supervision of regulatory and financial reporting teams and to ensure complying with the funds' regulatory requirements and corporate governance standards.</p><p>Previous to such roles, Mr. Bathurst was an advisor to Lion Capital Advisers Limited from April 2003 to March 2004, and also an advisor to the board of management of LCF Rothschild Asset Management Limited from June 2002 to March 2003.</p><p>Mr Bathurst joined the management board at Credit Agricole Asset Management in London, U.K., from April 1995 to March 2002. He was responsible for the recruitment and development strategy for marketing, sales, financial reporting, controls and investor relations.</p><p>Mr. Bathurst graduated from the Royal Military Academy Sandhurst in November 1974.</p>",
                    },
                ]               
            },
            {
                "id":"mts",
                "name": "Management Team",
                "text": "Aptorum has a highly experienced management team made up of individuals who have held senior positions in international pharmaceutical and financial companies. The management team is responsible for the strategic direction, operations and success of the company.",
                "icons": "images/icons/Button5.png",
                "icons_overlay": "images/icons/Button5_overhit.png",
                "members":[
                    {
                        "name":"Dr. Keith Chan",
                        "img":"images/team/keithchan.png",
                        "title":"Chief Scientific Officer, Aptorum Group Limited",
                        "text":"<p>Dr. Keith Chan is the Chief Scientific Officer of Aptorum Group Limited. Dr. Chan assists the Group with strategizing its clinical programs and approaches with the US FDA and China FDA.</p><p>Dr. Chan was the founder of GloboMax and currently a Senior Advisor for the Cornerstone Intellectual Property Foundation in Taiwan. Currently, he is also serving as adjunct professor at the Graduate Institute of Intellectual Property, College of Commerce, National Chengchi University and adjunct professor and advisor at the Research Center for Drug Discovery, National Yang Ming University in Taipei, Taiwan. He is also serving as Director of International Affairs, GloboAsia LLC, Rockville, Maryland.</p><p>Dr. Chan co-founded GloboMax LLC, a drug development organization, in Hanover, Maryland, in July 1997, and served as consultant for numerous multi-national pharmaceutical biotech firms in the U.S, Europe and Asia. GloboMax LLC was acquired by ICON, plc. in August 2003, and Dr. Chan exited the operation. Prior to that, he had joined the U.S. FDA in 1995 as Director of Division of Bioequivalence, Office of Generic Drugs, responsible for managing and executing preclinical animal studies, bioassay development, Phases I to VI Pharmacokinetics, pharmacodynamics, bioavailability, bioequivalence studies, outside contract, regulatory submission, advanced drug delivery systems in vivo evaluation, and all phases of generic and new drug development. In addition, he has served as adjunct Professor at the School of Pharmacy, University of Maryland at Baltimore for many years and also as Adjunct Professor and National Board of Advisor, College of Pharmacy, University of Minnesota since 1984. Before, Dr. Chan worked for Ciba-Geigy Corporation in Ardsley, New York, for 15 years, and held various senior and management positions. He has published more than 150 abstracts and research articles in peer-reviewed journals and over 200 professional presentations. He was elected as Fellow of the American Association of Pharmaceutical Scientists (AAPS) in 1995 for his scientific accomplishments on drug absorption in humans.</p><p>Although much of his career has been based in the United States, Dr. Chan has also assisted Asian pharmaceutical and biotech companies over the last 14 years. He has organized numerous workshops and conferences in China, Taiwan, Hong Kong, Singapore and Korea. He lectures frequently in Asia and serves as a scientific advisor for many regulatory agencies in Asia. Over the last several years, he has successfully assisted many Asian companies in their technology transfers and licensing deals to and from the U.S., as well as with numerous regulatory submissions to the U.S. FDA.</p><p>Dr. Chan obtained his Ph.D. degree in Pharmaceutics from the University of Minnesota in January 1980.</p>",
                    },
                    {
                        "name":"Miss Sabrina Khan",
                        "img":"images/team/sabrinakhan.png",
                        "title":"Chief Financial Officer, Aptorum Group Limited",
                        "text":"<p>Miss Sabrina Khan is the Chief Financial Officer of Aptorum Group Limited. She leads our financial strategy and operations, as well as Investor Relations. She has extensive experience working at KPMG (Hong Kong) and Ernst &amp; Young LLP (Hong Kong). She was recently the regional financial controller in Asia for St. James&rsquo;s Place Wealth Management (Hong Kong), which St. James&rsquo;s Place Wealth Management Group (LON: STJ) is a FTSE100 company with &pound;85.7bn of client funds under management. Prior to that, she served as the senior finance manager of Neo Derm Group, a leading medical aesthetic group in Asia, taking care of its finance-related matters and China expansion. From August 2009 to May 2013, she served as the group senior finance manager of China Cord Blood Corporation (NYSE: CO), which is a subsidiary of Golden Meditech Holdings Limited (HK: 801), where she played an important role with the NYSE listing filings and investor relations as well as post IPO reporting. During her employment with China Cord Blood Corporation, she was actively involved in the issuance of convertible bonds to KKR and different mergers and acquisitions projects, facilitated and liaised with investment banks on due diligence and deal structuring and also involved in commercial negotiation with respect to major contract terms.</p><p>Miss Khan qualified as certified public accountant and graduated with a BBA (Hons) in Accounting &amp; Finance at The University of Hong Kong in 2003. She also obtained qualification as Advanced China Certified Taxation Consultant in 2015.</p>",
                    },
                    {
                        "name":"Professor Thomas Lee",
                        "img":"images/team/thomaslee.png",
                        "title":"Chief Executive Officer and Chief Scientific Officer, Aptorum Therapeutics Limited",
                        "text":"<p>Dr. Thomas Lee is the Chief Executive Officer and Chief Scientific Officer of Aptorum Therapeutics Limited, the wholly owned therapeutics holding company of Aptorum Group Limited. Dr. Lee currently serves as Assistant Professor in the School of Pharmacy, Faculty of Medicine, at The Chinese University of Hong Kong (&ldquo;CUHK&rdquo;) having joined the faculty in August 2013. Dr. Lee&rsquo;s key area research involves pharmaceutical research in drug delivery that focuses on formulation development of poorly soluble compounds for oral delivery.</p><p>Prior to academia, Dr. Lee accumulated big-pharma experience by spending a decade in two multinational pharmaceutical companies. He was with Novartis Pharmaceuticals Corporation from June 2003 and November 2008, and subsequently was recruited to Celgene Corporation to serve as a manager of the Formulations Research &amp; Development. He was employed with Celgene from November 2008 to July 2013.</p><p>Dr. Lee graduated with B.Pharm. (Hons) Degree from the formerly Department of Pharmacy at the CUHK in August 1995, and received his Ph.D. in Pharmaceutical Sciences (Drug Delivery) from the University of Wisconsin-Madison in the U.S in May 2003.</p>",
                        // "remark":"Appointments to commence in January 2018",
                    },
                ]                              
            },
            {
                "id":"sas",
                "name": "Scientific Advisors",
                "text": "Our scientific advisors support our efforts to identify, develop and commercialize novel therapies for patients and the healthcare industry. They represent a diverse collection of academic, industrial and regulatory expertise.",
                "icons": "images/icons/Button6.png",
                "icons_overlay": "images/icons/Button6_overhit.png",
                "members":[
                    {
                        "name":"Professor Nishant Agrawal",
                        "img":"images/team/agrawalnishant.png",
                        "title":"Senior Clinical Advisor, Aptorum Therapeutics Limited",
                        "text":"<p>Dr. Agrawal, MD, has been serving as the Director of Head and Neck Surgical Oncology, and Professor of Surgery at The University of Chicago School of Medicine since October 2015. He specializes in management of patients with benign and malignant tumors of the head and neck, and has been practicing Otolaryngology - Head and Neck Surgery, at The University of Chicago Medicine, and Center for Advanced Medicine, both in Chicago since 2009.</p><p>Dr. Agrawal's work has achieved international recognition in the field of head and neck surgical oncology, and head and neck cancer genetics. Under his leadership, a team of researchers completed a landmark study that examined the genome of head and neck squamous cell carcinoma. His team then followed up by publishing the genomic landscapes of the remaining major head and neck cancers, including esophageal squamous cell carcinoma, esophageal adenocarcinoma, medullary thyroid cancer, adenoid cystic carcinoma, and mucoepidermoid carcinoma. Dr. Agrawal then applied these findings to identify tumor DNA as a biomarker that improves cancer diagnostics in the saliva and plasma of patients with head and neck squamous cell carcinoma. His research is focused on the application of cancer genetics to design diagnostic approaches to reduce morbidity and mortality from head and neck cancer.</p><p>In addition to his clinical and research contributions, Dr. Agrawal is an accomplished educator--teaching medical students, residents, and fellows about the management of patients with head and neck cancer. Prior to joining the University of Chicago, Dr. Agrawal was an associate professor at Johns Hopkins University, which is also where he completed medical school in 2001, followed by internship and residency.</p><p>In addition, Dr. Agrawal was granted fellowships from the Memorial Sloan Kettering Cancer Center, New York (Head and Neck Surgical Oncology), and from Johns Hopkins University School of Medicine, Baltimore (Molecular Genetics). He holds numerous Memberships from accredited American medical associations and institutions.</p>",
                    },
                    {
                        "name":"Professor Chan Lik Yuen, Henry ",
                        "img":"images/team/henrychan.png",
                        "title":"Senior Clinical Advisor, Aptorum Therapeutics Limited",
                        "text":"<p>Professor Chan has been serving as an Assistant Dean (External Affairs) at the Faculty of Medicine at The Chinese University of Hong Kong (&ldquo;CUHK&rdquo;), where he is Head of the Division of Gastroenterology and Hepatology, Department of Medicine and Therapeutics, since January 2013.</p><p>Professor Chan specializes in Gastroenterology and Hepatology. Key areas of research interest include viral hepatitis, liver fibrosis, liver cancer, anti-viral therapy, and fatty liver disease. Other roles Professor Chan are involved with include being Director at the Institute of Digestive Disease, Director at the Centre for Liver Health, and Director at the Office of Global Engagement, among numerous other honorary appointments including being the Chairman for the Strategic and Technical Advisory Committee for Viral Hepatitis at the Western Pacific Regional Office of World Health Organization (&ldquo;WHO&rdquo;).</p><p>Professor Chan is a key investigator in over thirty phase 1 to phase 4 international trials on antiviral treatment of chronic hepatitis B and C, and is the global lead author in publications on peginterferon-alfa, peginterferon-lambda, telbivudine, tenofovir disoproxil fumarate, and tenofovir alafenamide for the treatment of viral hepatitis B. He has received numerous local, national, and international research awards including the Excellent Research Award by the Food and Health Bureau, Hong Kong in 2010 and 2014, and the National Award for Science and Technology Progress in 2012. He has published over 400 papers in peer-reviewed journals.</p><p>Professor Chan graduated in medicine and completed his doctoral degree at CUHK in August 2001. He joined the staff of the Prince of Wales Hospital in July 1993 and was appointed to a full professorship in the Department of Medicine and Therapeutics of CUHK in August 2008. He is currently a Fellow of the Hong Kong College of Physicians, a Fellow of the Royal College of Physicians of Edinburgh and London, a fellow of the American Association for the Study of Liver Diseases, and an Honorary Consultant at the Prince of Wales Hospital.</p>",
                    },
                    {
                        "name":"Professor Philip Wy Chiu",
                        "img":"images/team/philipchiu.png",
                        "title":"Senior Clinical Advisor, Aptorum Therapeutics Limited",
                        "text":"<p>Professor Philip Chiu has been a Professor of Department of Surgery, Institute of Digestive Disease since August 2010; Director of CUHK Jockey Club Minimal Invasive Surgical Skills Center since November 2011; Director of CUHK Chow Yuk Ho Technology Center for Innovative Medicine and Assistant Dean (External Affairs), Faculty of Medicine since 2013, all with association to The Chinese University of Hong Kong (&ldquo;CUHK&rdquo;).</p><p>Professor Chiu graduated from the Faculty of Medicine, CUHK in 1994 with two scholarships. He became a fellow of the Royal College of Surgeons of Edinburgh, Hong Kong Academy of Medicine in 2001 and received his Doctor of Medicine at CUHK in 2009. Prof. Chiu was the first to perform endoscopic submucosal dissection (&ldquo;ESD&rdquo;) for treatment of early GI cancers in Hong Kong. In 2010, he performed the first Per-oral Endoscopic Myotomy (&ldquo;P.O.E.M.&rdquo;) in Hong Kong. His research interests include upper gastrointestinal bleeding, esophageal cancer and Minimally Invasive and Robotic esophagectomy, novel endoscopic technologies for diagnosis of early GI cancers, ESD and novel endoscopic procedures as well as Natural Orifices Transluminal Endoscopic Surgery (&ldquo;NOTES&rdquo;).</p><p>Currently he is honorary treasurer of the College of Surgeons of Hong Kong. He has published more than 100 peer reviewed manuscripts and 4 book chapters. He has received numerous prestigious awards including State Scientific Technology and Progress Award from People&rsquo;s Republic of China in 2007 and 2nd class award in Technological Advancement, Ministry of Education of the People&rsquo;s Republic of China in 2011. Recently his research on P.O.E.M. was awarded best of DDW 2011 and first prize of ASGE world cup of endoscopy 2012. He is currently associate editor for Digestive Endoscopy and co-editor of Endoscopy.</p>",
                    },
                    {
                        "name":"Professor Vincent Mok Chung Tong",
                        "img":"images/team/vincentmok.png",
                        "title":"Senior Clinical Advisor, Aptorum Therapeutics Limited",
                        "text":"<p>Professor Vincent Mok has been serving as the Assistant Dean (Admissions) at the Faculty of Medicine, The Chinese University of Hong Kong (&ldquo;CUHK&rdquo;) since January 2014, Head of Division of Neurology of the Department of Medicine and Therapeutics, since&nbsp;December 2016 and was appointed as the Mok Hing Yiu Professor of Medicine since November 2017. He has also been serving in Master Programme in Stroke and Clinical Neurosciences since July 2007.</p><p>Professor Mok specializes in Neurology, Dementia, and Movement disorders. Key areas of research interest include Vascular Cognitive Impairment, Cerebral Small Vessel Disease, Neuroimaging in Cognitive Impairment, and Parkinson&rsquo;s Disease. Other roles Professor Mok is involved with include being a Convener of Lui Che Woo Institute of Innovative Medicine - Brain Theme since January 2017, the Director of Therese Pei Fong Chow Research Centre for Prevention of Dementia since May 2016, and&nbsp;Executive Committee Member of Chow Yuk Ho Technology Center for Innovative Medicine since&nbsp;January 2015.</p><p>Professor Mok&rsquo;s qualifications include: Doctor of Medicine at CUHK (December 2005), Fellow of the Royal College of Physicians (Edinburgh) (July 2007), Fellow of the Hong Kong Academy of Medicine (December 2000), Fellow of the Hong Kong College of Physicians (July 2000), Member of the Royal College of Physicians (November 1996), and Bachelor of Medicine and Bachelor of Surgery (University of Sydney) (April 1993).</p>",
                    },
                    {
                        "name":"Dr. William Wu",
                        "img":"images/team/williamwu.png",
                        "title":"Scientific Assessment Committee Member, Aptorum Therapeutics Limited",
                        "text":"<p>Dr. William Wu has been an Assistant Professor in the Department of Anaesthesia and Intensive Care at The Chinese University of Hong Kong (&ldquo;CUHK&rdquo;) since December 2014. Prior, Dr. Wu was appointed as a Research Assistant Professor in the Institute of Digestive Diseases at CUHK between December 2011 and November 2014. He is an expert in molecular pharmacology and toxicology. He has published extensively in cancer biomarker diagnostics and novel therapeutics. He has published over 200 peer-reviewed articles in top international journals, including Nature Communications, Molecular Biology and Evolution, Autophagy, Cell Research, and Cancer Research, and four book chapters with citations over 6,000 and an h-index of 40 (Scopus). His research has been recognized both nationally and internationally. He has earned his Fellowship of the Royal College of Pathologists (FRCPath) from his original works in toxicology, and has been conferred the Young Research Award by CUHK, the First-Class Higher Education Outstanding Scientific Research Output Award (Natural Science) by the Ministry of Education of China, and the Second-Class State Natural Science Award.</p><p>Dr. Wu obtained his Ph.D. in Medical Sciences in December 2009 and received post-doctoral training from 2009 to 2011 in the Institute of Digestive Diseases both from CUHK.</p>",
                    },
                    {
                        "name":"Dr. Jason Y.K. Chan",
                        "img":"images/team/jasonchan.png",
                        "title":"Scientific Assessment Committee Member, Aptorum Therapeutics Limited",
                        "text":"<p>Dr. Jason Chan serves as an Assistant Professor in the Department of Otorhinolaryngology, Head &amp; Neck Surgery at The Chinese University of Hong Kong (&ldquo;CUHK&rdquo;) since September 2014. Between June 2012 and September 2014, Dr. Chan satisfied the Hong Kong Medical Council's requirements to practice medicine in Hong Kong while obtaining his certification from American Board of Otolaryngology and continuing his research interests. Professor Chan graduated from Guy&rsquo;s, King&rsquo;s and St Thomas&rsquo; School of Medicine in London in July 2005, followed by completion of specialist training in Otolaryngology, Head and Neck surgery at the Johns Hopkins School of Medicine with advanced training in Head and Neck Surgery on microvascular reconstruction and robotics in June 2013.</p><p>His research interests include the genomics, microbiome, diagnosis, treatment and surveillance of head and neck cancers and the development of novel robotic applications for head and neck surgery.</p><p>Dr. Chan&rsquo;s qualifications: License of Medical Council of Hong Kong, Bachelor of Medicine and Bachelor of Surgery (London), Diplomate American Board of Otolaryngology, Head and Neck Surgery, Fellow of the Hong Kong College of Otorhinolaryngology, Fellow of the Hong Kong Academy of Medicine (Otorhinolaryngology), Feloow of the Royal College of Surgeons Edinburgh (Otorhinolaryngology).</p>",
                    },
                    {
                        "name":"Dr. Kwok, Ka Wai",
                        "img":"images/team/kawaikwok.png",
                        "title":"Scientific Assessment Committee Member, Aptorum Therapeutics Limited",
                        "text":"<p>Dr. Ka-Wai Kwok has been serving as Assistant Professor in Department of Mechanical Engineering, The University of Hong Kong (HKU) since August 2014. He has also been serving as an Adjunct Assistant Professor in the School of Science and Engineering at The Chinese University of Hong Kong, Shenzhen (&ldquo;CUHK(SZ)&rdquo;), since October 2016. He completed his Ph.D. training in The Hamlyn Centre for Robotic Surgery, Department of Computing, Imperial College London in September 2011, where he continued research on surgical robotics as a postdoctoral fellow between September 2011 and May 2013, and obtained the Croucher Foundation Fellowship between August 2013 and August 2014. This subsequently supported his research jointly hosted by The University of Georgia and Brigham and Women's Hospital - Harvard Medical School. His research interests focus on surgical robotics, intra-operative medical image processing, and their uses of high-performance computing techniques. To date, he has been involved in various designs of surgical robotic devices and interfaces for endoscopy, laparoscopy, stereotactic and intra-cardiac catheter interventions. His work has also been recognized by several awards from IEEE international symposium/conferences, including RCAR'17, ICRA&rsquo;17, ICRA&rsquo;14, IROS&rsquo;13 and FCCM&rsquo;11, and Surgical Robot Challenge'16. He also became the recipient of Early Career Awards 2015/16 offered by Research Grants Council (RGC) of Hong Kong.</p>",
                    },
                    {
                        "name":"Dr. Kenny Yu",
                        "img":"images/team/kennyyu.png",
                        "title":"Scientific Assessment Committee Member, Aptorum Therapeutics Limited",
                        "text":"<p>Dr. Kenny Yu was appointed as NIHR Academic Clinical Lecturer based at the University of Manchester in the United Kingdom in 2017. He completed his Ph.D. in 2016 at the Stem Cell and Neurotherapies Laboratory at the University of Manchester under Prof Brian Bigger and subsequently completed a post-doctoral research fellowship at Dr. Peter Dirks laboratory in Toronto, Canada. He is currently also completing specialist training in Neurosurgery at Salford Royal Hospital, United Kingdom, in which the training had started in 2008. His research interests are in myeloid cell infiltration in malignant gliomas, intra-tumoral delivery of therapeutics and in the application of advanced data analytical technologies for biological and clinical datasets.</p><p>Dr. Yu&rsquo;s key areas of research interests include Neurosurgery, Neuro-oncology, Cancer inflammation and Cancer Immunology.</p>",
                    },
                    {
                        "name":"Dr. Owen Ko",
                        "img":"images/team/owenko.png",
                        "title":"Scientific Assessment Committee Member, Aptorum Therapeutics Limited",
                        "text":"<p>Dr. Ko has been serving as a principal investigator at the Gerald Choa Neuroscience Center since 2017, a principal investigator at the Li Ka Shing Institute of Health Sciences and a clinical lecturer in the Department of Medicine and Therapeutics since 2016, with all appointments at The Chinese University of Hong Kong (&ldquo;CUHK&rdquo;). Leading a team with diverse expertise in biology, chemistry and engineering, his research work focuses on the principles by which neural circuits mediate sensory perception and learning, as well as development of novel neuroimaging techniques.</p><p>Dr. Ko was admitted to the Bachelor of Medicine and Bachelor of Surgery Programme (MBChB) at CUHK in 2005. After completing his second year of studies, he pursued a one-year Intercalated Bachelor of Medical Sciences (BMedSci), followed by a three-year Ph.D. program in neuroscience at University College London (&ldquo;UCL&rdquo;) in the UK under the guidance of Professor Thomas Mrsic-Flogel. In 2012, Dr. Ko returned to Hong Kong and completed clinical training in 2015. He has published two first-authored Nature papers and one first-authored Nature Neuroscience paper from his Ph.D. studies. His breakthrough research has led to his runner-up award of the 2014 Eppendorf &amp; Science Prize for Neurobiology, as the first awardee in Hong Kong.</p>",
                    },
                    {
                        "name":"Dr. Wai-Lung Ng",
                        "img":"images/team/wailungng.png",
                        "title":"Scientific Assessment Committee Member, Aptorum Therapeutics Limited",
                        "text":"<p>Dr. Wai-Lung Ng obtained his B.Sc. degree with First Class Honors in Chemistry from The Chinese University of Hong Kong (&ldquo;CUHK&rdquo;) in 2010. With the support of the Hong Kong Ph.D. Fellowship and T.C. Cheng Postgraduate Scholarship, he completed his Ph.D. studies at CUHK in 2014. He was a Fulbright Scholar (2013-2014) at Massachusetts Institute of Technology (MIT), under the funding support from the Lee Hysan Foundation and the Fulbright Program. He then researched at University of Oxford as a Croucher Foundation Postdoctoral Fellow from 2014-2016.</p><p>He has strong interest in understanding diseases on the molecular basis with a goal to develop tools to diagnose and treat them. His Ph.D. research centers on the syntheses of a new class of anti-diabetic agents, namely sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. His research works have already led to the identification of several stable, potent and selective SGLT2 inhibitors that may provide an alternative solution for treating diabetes.</p><p>Dr. Ng is currently researching in the field of chemical biology and cancer epigenetics at Dana-Farber Cancer Institute / Harvard Medical School. The central aim of his research is to uncover the underlying mechanism of epigenetic regulations and to develop novel treatments for cancers and other human diseases.</p>",
                    },    
                    {
                        "name":"Dr. Sunny H. Wong",
                        "img":"images/team/sunnywong.png",
                        "title":"Scientific Assessment Committee Member, Aptorum Therapeutics Limited",
                        "text":"<p>Dr. Sunny Wong is an Assistant Professor in the Department of Medicine and Therapeutics at The Chinese University of Hong Kong (&ldquo;CUHK&rdquo;), and Principal Investigator at the Li Ka Shing Institute of Health Science, the Institute of Digestive Disease and the State Key Laboratory of Digestive Disease, all since December 2013.&nbsp;</p><p>Dr. Wong has been specializing as a Gastroenterologist and Physician-Scientist with expertise in genomics and molecular microbiology since December 2016. He is leader of the Clinical Metagenomics Research Group, with a focus to study the mechanistic role and translational potential of host-microbial interactions in diseases; having been the group leader since December 2013. He has published more than 60 peer-reviewed articles in international journals, including the New England Journal of Medicine, Nature Genetics, Nature Communications, Gastroenterology and Gut as of December 2017. He has been an investigator in epidemiological studies and clinical trials, and is a member of the local clinical research ethics committee since September 2016.</p><p>Dr. Wong&rsquo;s qualifications: MBChB (Hons) (CUHK) (June 2006); DPhil (Oxon) (June 2010); MRCP (UK) (February 2012); FHKCP (October 2016); FHKAM (Medicine) (December 2016); FRCP (Edin) (September 2017); FRCPath (Expected February 2018).</p>",
                    },                
                ]                           
            }
        ],
    },
    "news":{
        "title":"News",
        "press":[
            {                
                "name": "html_news_rthk_01",
                "ishtml": true,
                "href":"http://www.rthk.hk/radio/radio1/programme/NovaManagement/episode/470079",
                "title": "ç®¡ç†æ–°æ€ç»´ - çº¢é¡¶å•†äººèƒ¡é›ªå²©",
                "place":"é¦™æ¸¯ç”µå°ç¬¬ä¸€å°",
                "date":"11 Nov 2017",
                "caption": "ä¸»æŒäººï¼šé™ˆå¿—è¾‰ã€å†¼æ—¥æ˜Žã€ æ½˜å˜‰é˜³ã€æŽé™å®œã€ç¨‹æ´æ˜Ž<br>å˜‰å®¾ï¼šç¦¤éªè¿œï¼ˆçŸ¥ä¸´é›†å›¢é¦–å¸­æ‰§è¡Œå®˜åŠåˆ›å§‹äºº)",
            },
            {                
                "name": "html_video_tvb_01",
                "ishtml": true,
                "href":"http://news.tvb.com/programmes/mediinfocancerii/59ec3e70e60383c923287999",
                "title": "ç™Œç—‡ç³»åˆ—II - å¤§è‚ ç™Œï¼ˆäºŒï¼‰@æ— çº¿æ–°é—»",
                "place":"æ— çº¿æ–°é—»",
                "date":"22 Oct 2017",
                "caption": "Justin Wu @ æ— çº¿æ–°é—»",
            },
            {                
                "name": "video_what_is_ad",
                "title": "æŸé‡‘é€Šç—‡200å‘¨å¹´å¥åº·æ•™è‚²çŸ­ç‰‡ç³»åˆ—é¦™æ¸¯è¿åŠ¨éšœç¢å­¦ä¼šå‘ˆçŒ®",
                "place":"The Hong Kong Movement Disorder Society",
                "date":"07 Aug 2017",
                "caption": "æŸé‡‘é€Šç—‡200å‘¨å¹´å¥åº·æ•™è‚²çŸ­ç‰‡ç³»åˆ— - ç¬¬ä¸€é›†ï¼šä»€ä¹ˆæ˜¯æŸé‡‘é€Šç—‡ï¼Ÿ<br>è®²å¸ˆï¼šèŽ«ä»²æ£ æ•™æŽˆï¼ˆé¦™æ¸¯è¿åŠ¨éšœç¢å­¦ä¼šå‰ä¼šé•¿åŠè„‘ç¥žç»ç§‘ä¸“ç§‘åŒ»ç”Ÿï¼‰",
            },
            {                
                "name": "html_news_am730_01",
                "ishtml": true,
                "href":"https://www.am730.com.hk/news/%E5%81%A5%E5%BA%B7/%E4%B8%AD%E5%A4%A7%E7%A0%94%E7%A9%B6%E8%AA%8D%E8%AD%98%E7%A5%9E%E7%B6%93%E7%96%BE%E7%97%85-%E6%8B%86%E8%A7%A3%E5%A4%A7%E8%85%A6%E5%AD%B8%E5%8B%95%E4%BD%9C%E5%8E%9F%E7%90%86-85499",
                "title": "ä¸­å¤§ç ”ç©¶è®¤è¯†ç¥žç»ç–¾ç—… - æ‹†è§£å¤§è„‘å­¦åŠ¨ä½œåŽŸç† @ AM730",
                "place":"AM730",
                "date":"05 Jul 2017",
                "caption": "é«˜æµ©åšå£«ä¸Žè„‘ç¥žç»ç§‘å­¦ä¸­å¿ƒå›¢é˜Ÿ",
            },
            {                
                "name": "video_event_all",
                "title": "Videns Life Sciences Launch Cocktail Event Highlights",
                "place":"Island Shangri-La",
                "date":"22 Jun 2017",
                "caption": "Videns Life Sciences, a member of the APTUS Therapeutics Group, is the first Hong Kong based company focused in the Large-Scale Strategic Clinical Development in Neurodegenerative Disease and Imaging Diagnosis Innovation. Here are the highlights from the companyâ€™s official Launch Cocktail Event held in Island Shangri-La, Hong Kong.",
            },
            {                
                "name": "video_xinglin_vincent_mok",
                "title": "ã€ææž—åœ¨çº¿ã€‘è§†ç½‘è†œè¡€ç®¡æ£€æµ‹ä¸­é£Žé£Žé™©",
                "place":"Now TV",
                "date":"08 Mar 2017",
                "caption": "ã€ææž—åœ¨çº¿ã€‘è§†ç½‘è†œè¡€ç®¡æ£€æµ‹ä¸­é£Žé£Žé™© - ä¸­æ–‡å¤§å­¦èŽ«ä»²æ£ æ•™æŽˆè¯¦ç»†è®²è§£ã€‚",
            },
            {                
                "name": "video_kwgroup",
                "title": "é«˜æµ©åšå£«@å˜‰äº‹ä¸“é¢˜",
                "place":"å˜‰äº‹ä¸“é¢˜",
                "date":"20 Sep 2017",
                "caption": "é«˜æµ©åšå£«åœ¨å˜‰äº‹ä¸“é¢˜æŽ¥å—è®¿é—®@ 11ï¼š49",
            },
            {                
                "name": "html_news_wenwei_01",
                "ishtml": true,
                "href":"http://paper.wenweipo.com/2014/09/10/YO1409100013.htm",
                "title": "å¹´è½»ç¥žç»ç§‘å­¦å®¶è§£è„‘è°œ@é¦™æ¸¯æ–‡æ±‡æŠ¥",
                "place":"é¦™æ¸¯æ–‡æ±‡æŠ¥",
                "date":"10 Sep 2014",
                "caption": "é¦™æ¸¯æ–‡æ±‡æŠ¥ - é«˜æµ©åšå£«ä¸“è®¿",
            },
        ]
    },
    "investor":{
        "title":"Event",        
        "text":"Access Aptorumâ€™s due diligence Data Room here.",
        "dataroomurl":"http://investor.aptorumgroup.com",
    },
    "contact": {
        "title": "Aptorum Group",
        "text": "We value your interst in Aptorum Group. Should you have any pressing questions with regards to investor informat, please leave us your contact information.",
        "callus": "<span>Have a Question? </span><span>Call us at </span><span>+852 2117 6611</span>",
        "address": "17/F, Guangdong Investment Tower, 148 Connaught Road Central,Hong Kong",
        "tel": "+852 2117 6611",
        "fax": "+852 2850 7286",        
        "placeholders":
        {
            "name":"Name (required)",
            "email":"Email (required)",
            "subject":"Subject",
            "message":"Your Message",            
        }
    },
    "translation": {
        "view_more": "VIEW MORE",
        "address":"Address",
        "tel":"Tel",
        "fax":"Fax",
        "nameError":"Please enter your name.",
        "emailError":"Please enter your e-mail address.",
        "invalidEmailError":"Please enter a valid e-mail address.",
        "subjectError":"Please enter the subject.",
        "messageError":"Please enter your message.",
        "mailSuccess":"Your message has been sent. Thank you!",
        "captchaText":"Please enter above text.",
        "nocaptchaError":"Please enter validation key.",
        "invalid_captcha":"Invalid validation key",
        "datatable":{
            "language": {
                "lengthMenu": "Display _MENU_ records per page",
                "zeroRecords": "Nothing found - sorry",
                "info": "Showing page _PAGE_ of _PAGES_",
                "infoEmpty": "No records available",
                "infoFiltered": "(filtered from _MAX_ total records)",
                "search": "Search:",
            },
            "headers":{
                "date": "Date",
                "title": "Title"
            }
        },
        "pressrelease":"Press Release",
        "termofuse":"Terms of Use",
    },
}